Extensive, late-stage radiopharmaceutical pipeline
Our core product pipeline, focused on prostate, renal (kidney), glioblastoma (brain) and hematologic cancers (bone marrow conditioning) is based on decades of clinical experience and real patient outcomes.
Our investigational diagnostic products have the potential to guide treatment decisions, while our therapeutic candidates have potential to deliver personalised precision medicine.
Shaded sections Indicate expected development stage in the next 12 months.
1. Prostate-specific membrane antigen.
2. Carbonic anhydrase IX.
3. Large amino acid transporter 1.
4. Bone Marrow Conditioning/Rare Diseases.
5. Cluster of differentiation 66.